Expertise in
48
conditions

Olivier Fain

Paris, FR 
Expertise in
48
conditions
Paris, FR 

Overview

Olivier Fain practices practicing medicine in Paris, France.

Mr. Fain is highly rated in 48 conditions, according to our data. His clinical expertise encompasses Angioedema, Hives, Hereditary Angioedema, Splenectomy, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 419 peer reviewed articles and participating in 10 clinical trials.

Gender

Male

Locations

Paris, France
Other Locations
Saint Antoine, France
Creteil, France
Grenoble, 38043, France
Bobigny, France
Avenue De La Côte De Nacre, Caen, 14003, France
Saint-jean-saint-germain, France
Pierre-la-treiche, France
Bondy, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Enrollment Status: Completed
Publish Date: March 24, 2026
Intervention Type: Drug
Study Drugs: Steroid, Cyclophosphamide, Rituximab
Study Phase: Phase 3
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
Enrollment Status: Completed
Publish Date: March 20, 2026
Intervention Type: Other, Biological
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: January 20, 2026
Intervention Type: Drug
Study Phase: Phase 4
Regulatory T-cell Induction by Low-dose Interleukin-2 in Women With Unexplained Repeated Spontaneous Early Miscarriages
Regulatory T-cell Induction by Low-dose Interleukin-2 in Women With Unexplained Repeated Spontaneous Early Miscarriages
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Study Phase: Phase 3
Icatibant Outcome Survey (IOS) Registry
Icatibant Outcome Survey (IOS) Registry
Enrollment Status: Completed
Publish Date: October 28, 2024
Retrospective, Observational Chart Review Study Evaluating Clinical Effectiveness and Disease/Treatment Management Among Patients Who Initiated Long-term Prophylaxis With Takhzyro® in a Real-world Setting
Retrospective, Observational Chart Review Study Evaluating Clinical Effectiveness and Disease/Treatment Management Among Patients Who Initiated Long-term Prophylaxis With Takhzyro® in a Real-world Setting
Enrollment Status: Completed
Publish Date: January 13, 2023
Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach
Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach
Enrollment Status: Completed
Publish Date: July 20, 2021
Intervention Type: Drug
Study Drug: IL-2
Study Phase: Phase 2
Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study
Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study
Enrollment Status: Completed
Publish Date: August 19, 2020
Intervention Type: Drug
Study Phase: Phase 3
Prospective Multicentre Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® by Intrathecal Injection in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
Prospective Multicentre Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® by Intrathecal Injection in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
Enrollment Status: Completed
Publish Date: August 23, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

418 Total Publications

Title Not Found
Title Not Found
Journal: La Revue du praticien
Published: March 25, 2026

Frequently Asked Questions about Olivier Fain

Is Olivier Fain a top-rated expert for Angioedema?

MediFind is an objective health platform that identifies experts based on real-world data. Olivier Fain is classified as an Elite expert for Angioedema, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Olivier Fain participate in research or clinical trials?

Yes. Olivier Fain has published 418 articles and abstracts on conditions like Angioedema. You can view a list of Olivier Fain's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fain's expertise for a condition
ConditionClose
View All 15 Distinguished Conditions
View All 27 Advanced Conditions
View All 94 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile